Startup Stage: Company – 2016, Luxembourg | TRL9 / CRL9
Value Proposition: A plasma nanocoating system to help manufacturers improve adhesion, wettability, and surface functionality by grafting chemistries in a single solvent‑free step with proprietary platforms enabling durable, eco‑friendly, and scalable solutions
Product: Materials
Market: Health
IP: License | 1 Patent
Founders (ext.): Executive Chairman, Marc Jacobs | CEO, Peter Vansant | CTO, Joanna Borek-Donten | CFO, Stijn Vansant | Employees, 30+
Contact (int.): Ventures, Alex Godlewski
Revenue: Revenue growth, ~€3.5M - Hospitals
Funding: Pre-Seed (Angels, Fit 4 Start) | €1M+ raised in total
